Asset
LTI-03
Rein Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06968845 | phase2 | recruiting | 2026-02-02 | 2027-09-30 | Rein Therapeutics | A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis |
| NCT05954988 | phase1 | completed | 2023-07-06 | 2024-09-25 | Rein Therapeutics | A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients |
FDA applications (0)
This company has no applications containing this asset.